HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on Regenxbio (NASDAQ:RGNX) and raises the price target from $36 to $38.
May 15, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on Regenxbio and raises the price target from $36 to $38.
The Buy rating and increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100